Colorcon opens new formulation services facility in Bogota, Colombia
This specially designed facility has internationally recognized certification for the containment and safe handling of Level II and Level IV APIs, and will provide customer’s faster turnaround on technical services and increased capacity to handle more projects.
Colorcon has announced the opening of a new Technical Service, Laboratory and Conference Facility in Bogotá, Colombia, to support market growth and customers across the Andean countries, Central America and the Caribbean. The new facility is strategically located close to transportation hubs to service the pharmaceutical industry across this region.
This specially designed facility has internationally recognized certification for the containment and safe handling of Level II and Level IV APIs, and will provide customer’s faster turnaround on technical services and increased capacity to handle more projects. Carlos LaCruz, Regional Sales Manager explains the importance of this facility to the region “The laboratory is fully equipped to handle Level II and Level IV APIs, for research scale solid dose development. This capability is of particular importance for our customers who require this type of equipment and containment capabilities. We can provide specialized support to accelerate development and commercialization of robust, high quality pharmaceutical drug formulations”.
Plinio Sandoval, Regional Technical Manager stated: “To shorten customer’s formulation development time, Colorcon has invested in new‐instrumented equipment, including high shear granulation, an instrumented press machine, advanced film coating equipment and USP dissolution apparatus. Access to this advanced technology and analytical tools enables more robust formulation development, provides release profiles and ultimately better prediction for scale‐up to manufacturing.”
The Technical Center provides the capacity to increase the educational programs offered, with additional Colorcon Coating and Formulation Schools included to the 2016 schedule; plus a new Formulation School for Matrices addressing the markets’ continuing interest for modified release products.
Perry Cozzone, President — Americas added: “This investment demonstrates Colorcon’s continued commitment to reducing our customer’s time to market and making a positive contribution to their manufacturing quality and production efficiency. It reinforces our dedication to providing best‐in‐class products and services through a network of laboratories positioned close to our customers. The combination of our high quality products and this unprecedented service model is the value of Colorcon.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance